Skip to main content

Table 1 Patient characteristics

From: CT-based peritumoral radiomics signatures to predict early recurrence in hepatocellular carcinoma after curative tumor resection or ablation

Characteristics Training Set (N = 109) Validation Set (N = 47) P
Gender (Male/ Female) 59/50 29/18 0.25
Age (Mean ± SD) 53.2 ± 12.4 55.4 ± 10.6 0.29
Preoperative AFP (Mean ± SD) (ng/mL) 946.7 ± 50,371.4 7891.4 ± 3530.9 1.00
Cirrhosis (positive/negative) 67/42 28/19 0.82
Hepatitis (positive/negative) 96/13 42/5 0.82
Number of nodules (1/≥2) 87/22 33/14 0.35
Lesion diameter (Mean ± SD) (cm) 4.2 ± 2.9 3.9 ± 3.3 0.57
Treatment method (resection/ablation) 33/76 18/29 0.15
ER (%) 50/109(45.9) 25/47(53.2) 0.51
PT-E positive rate (%) 23/109 (21%) 16/47 (34%) 0.13
T-RO risk score (mean ± SD) 0.46 ± 0.28 0.43 ± 0.36 0.58
PT-RO risk score (mean ± SD) 0.46 ± 0.26 0.44 ± 0.29 0.67
  1. SD standard deviation, AFP alpha-fetoprotein. Hepatitis, Hepatitis B or C; ER early recurrence, PT-E peritumoral enhancement, T-RO tumoral radiomics, PT-RO peritumoral radiomics, T-RO risk score refers to the application of T-RO model to the image of the cases in the training and validation sets, and obtain the risk score of each case (the output is the specific value, 0–1). PT-RO risk score refers to the application of PT-RO model to the image of the cases in the training and validation sets, and obtain the risk score of each case (the output is the specific value, 0–1). P-value reflected the differences between the training and validation cohorts, and P values of less than 0.05 (two-sided) were considered statistically significant